---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-034774"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:21:12.123898+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nasdaq panel grants Avenue Therapeutics extension to May 20, 2024 for listing compliance

## Summary
- Nasdaq Hearings Panel granted extension through May 20, 2024 to meet stockholders' equity and bid price requirements.
- Company must evidence closing bid price >= $1.00 for at least 10 consecutive business days by May 20, 2024.
- Previously failed to regain compliance by Nov 15, 2023; delisting process had been stayed pending hearing.
- No assurance of regaining compliance; company evaluating all available options.

## SEC filing metadata
- accession: 0001104659-24-034774
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465924034774/0001104659-24-034774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465924034774/tm248839d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-034774
- JSON: https://secwatch.observer/filing/0001104659-24-034774.json
- Plain text: https://secwatch.observer/filing/0001104659-24-034774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.